Stock Analysis
Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Reports First Quarter 2024 Earnings
Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (HKG:1349) First Quarter 2024 Results
Key Financial Results
- Revenue: CN¥147.6m (down 22% from 1Q 2023).
- Net income: CN¥2.35m (down 73% from 1Q 2023).
- Profit margin: 1.6% (down from 4.6% in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd shares are up 1.9% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd has 3 warning signs (and 1 which is a bit concerning) we think you should know about.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:1349
Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd
Engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China.
